PureTech Health plc

Equities

PRTC

GB00BY2Z0H74

Biotechnology & Medical Research

Market Closed - London S.E. 12:35:03 2024-03-28 pm EDT 5-day change 1st Jan Change
222.5 GBX -1.11% Intraday chart for PureTech Health plc +1.60% +14.57%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ADRs End Flat, Ehang Holdings Ltd. Climbs 15.6% DJ
European large-caps rise on eve of Fed decision AN
Tranche Update on PureTech Health plc's Equity Buyback Plan announced on May 5, 2022. CI
PureTech shares jump on USD100 million tender offer proposal AN
PureTech Health to Return $100 Million to Shareholders via Tender Offer MT
PureTech Health Proposes $100 Million Capital Return MT
PureTech Health: Bristol Myers Squibb Wraps Up $14 Billion Acquisition of Karuna MT
PureTech Health: Bristol Myers Squibb Wraps Up $14 Billion Acquisition of Karuna MT
PureTech Health Says US FDA Grants Orphan Drug Label to LYT-200 to Treat Acute Myeloid Leukemia MT
PureTech Health celebrates drug designation for LYT-200 from US FDA AN
PureTech Gets FDA Orphan Designation for LYT-200 in Acute Myeloid Leukemia DJ
PureTech notes positive results from Shionogi's EndeavorRx ADHD trial AN
PureTech Health plc's Equity Buyback announced on May 5, 2022, has closed with 19,429,491 shares, representing 6.88% for $50 million. CI
Transcript : PureTech Health plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:00 AM
ADRs End Higher; FLJ Group Climbs 45% DJ
ADRs Advance, Argo Blockchain PLC Climbs 35.0% DJ
PureTech makes strong progress, expects "multiple catalysts" next year AN
PureTech Health Provides Updates on Programs, Reports Strong Financial Position MT
PureTech Health Says Early Stage Trial of Solid Tumor Therapy Showed Disease Control, Favorable Safety Profile MT
N4 launches investor hub; Capricorn production falls AN
PureTech hails schizophrenia trial results for Karuna drug AN
UK retail sales fall; AstraZeneca gets US approval AN
PureTech Health's Phase 2a Trial of LYT-300 to Treat Anxiety Meets Primary Endpoint MT
PureTech Health celebrates positive results in Phase 2 anxiety trial AN
Puretech Health plc Announces Topline Results from Its Phase 2A, Randomized, Placebo-Controlled, Proof-Of-Concept Trial of LYT-300 CI
Chart PureTech Health plc
More charts
PureTech Health plc is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has developed 27 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx) that have received both United States (US) Food and Drug Administration (FDA) clearance and European marketing authorization. The Company's pipeline includes LYT-100, LYT-200, LYT-300, LYT-310 and LYT-503/IMB-150. LYT-100 (deupirfenidone) is being advanced for the potential treatment of conditions involving inflammation and fibrosis. It is developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. LYT-300 is an oral prodrug of allopregnanolone, which is being advanced for the potential treatment of anxiety disorders and postpartum depression.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.813 USD
Average target price
5.911 USD
Spread / Average Target
+110.15%
Consensus
  1. Stock
  2. Equities
  3. Stock PureTech Health plc - London S.E.
  4. News PureTech Health plc
  5. PureTech Starts Late-Stage Study of LYT-100 to Treat Idiopathic Pulmonary Fibrosis